Genmab AS Aktie - GE9

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

188,35

Gebot

187,90

Fragen

188,00

Volumen

107

188,35 Tagesbereich 190,20

155,00 52-Wochen-Bereich 275,50

Marktkapitalisierung

12,373B

Handelsende

187,20

Handelsbeginn

189,00

Letzte Trade

188.35

Letzter Handelszeitpunkt

10:22:28

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

453

Ausgegebene Aktien

65.691.573

Dividendenrendite

Kurs-Gewinn-Verhältnis

1,57

Gewinn pro Aktie (EPS)

119,41

Erlöse

21,53B

Nettogewinn

7,84B

Sektor

Biological Pds,ex Diagnstics

Branche

Biogenetic (human)

Website

www.genmab.com

Hauptsitz

Copenhagen, Dnk

Gegründet

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 187,20 €. Over the last year, Genmab AS shares have traded in a share price range of 155,00 € to 275,50 €.

Genmab AS currently has 65.691.573 shares in issue. The market capitalisation of Genmab AS is 12,30 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 1.57.

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting...

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab...

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq:...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Genmab Announces Financial Results for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024 May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 5, 2025 – Genmab A/S (Nasdaq: GMAB). On March...

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	15.1	8.71572871573	173.25	190.2	173.15	214	183.55401119	DE
4	7.3	4.03203534935	181.05	192.85	161.8	285	181.20998708	DE
12	-29.05	-13.3624655014	217.4	223.8	155	453	185.94465586	DE
26	-10.1	-5.08944318468	198.45	223.8	155	447	193.22983307	DE
52	-87.15	-31.6333938294	275.5	275.5	155	349	207.0929418	DE
156	-171.25	-47.6223581758	359.6	362.9	155	263	223.61336301	DE
260	-185.25	-49.585117773	373.6	374.3	155	223	224.16332366	DE

GE9 - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is 188,35 €

How many Genmab AS shares are in issue?

Genmab AS has 65.691.573 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is EUR 12,3B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of 155,00 € to 275,50 € during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 1,57

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 0,57

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 21,53B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 7,84B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SS6Pan American Energy Corp	0,21 € (36,36%)	200
CNM1Carnegie Clean Energy Limited	0,0338 € (30,00%)	5,3k
34Q0Quantum eMotion Inc	0,628 € (28,43%)	887,55k
Z620Trillion Energy International Inc	0,0299 € (24,07%)	17,5k
CBOImunon Inc	0,45 € (22,28%)	450
L7C2Windfall Geotek Inc	0,0055 € (-56,00%)	11,19k
SL51Vanguard Mining Corp	0,0605 € (-41,26%)	3,5k
DN3Metaplanet Inc	5,24 € (-37,47%)	2,93M
VJFVital Metals Ltd	0,0011 € (-26,67%)	500k
42FBAIML Innovations Inc	0,0486 € (-23,58%)	253
DN3Metaplanet Inc	5,24 € (-37,47%)	2,93M
D7GNel ASA	0,2114 € (-1,95%)	1,1M
DMLSayona Mining Limited	0,0093 € (1,09%)	988,21k
VSLDigital X Ltd	0,036 € (-9,09%)	944k
34Q0Quantum eMotion Inc	0,628 € (28,43%)	887,55k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program

Genmab Announces Financial Results for the First Quarter of 2024

Transactions in Connection with Share Buy-back Program

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program

GE9 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9) Börsenkurse

Genmab AS (GE9)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program

Genmab Announces Financial Results for the First Quarter of 2024

Transactions in Connection with Share Buy-back Program

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program

GE9 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen